First Turn Management’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$47.1M Buy
1,331,066
+140,948
+12% +$4.17M 5.04% 6
2026
Q1
$33M Buy
1,190,118
+3,301
+0.3% +$84.8K 3.68% 11
2025
Q4
$25.8M Buy
1,186,817
+227,114
+24% +$4.48M 2.94% 17
2025
Q3
$14.5M Buy
+959,703
New +$11.9M 2.18% 23
2024
Q1
Sell
-1,363,504
Closed -$15.3M 37
2023
Q4
$15.3M Buy
+1,363,504
New +$13.3M 2.2% 25

Other funds holding ROIV

First Turn Management's ROIV Position: Q2 2026 in Review

First Turn Management increased its Roivant Sciences (ROIV) stake by 12% in Q2 2026, buying an estimated $4.17M and bringing the position to 1,331,066 shares worth $47.1M. The position accounts for 5.04% of the portfolio, ranked #6.

First Turn Management first reported a position in ROIV in Q4 2023 and has held it in 5 quarters since. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • First Turn Management held 1,331,066 shares of Roivant Sciences worth $47.1M as of Q2 2026.
  • First Turn Management bought 140,948 Roivant Sciences shares in Q2 2026, an estimated $4.17M.
  • Roivant Sciences made up 5.04% of First Turn Management's portfolio in Q2 2026, its #6 holding.
  • First Turn Management first reported a position in Roivant Sciences in Q4 2023 and has held it in 5 quarters since.
  • 499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on First Turn Management's 13F filing for Q2 2026, filed 14 Aug 2026.